Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

  • ID: 3766797
  • Report
  • Region: Global
  • 48 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • CJ HealthCare Corp.
  • MorphoSys AG
  • Novartis AG
  • Vicore Pharma AB
  • MORE
Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

Summary

The report ‘Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
- The report reviews Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • CJ HealthCare Corp.
  • MorphoSys AG
  • Novartis AG
  • Vicore Pharma AB
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) Overview

Therapeutics Development

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Stage of Development

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Therapy Area

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Indication

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Companies

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Companies Involved in Therapeutics Development

CJ HealthCare Corp.

MorphoSys AG

Novartis AG

Vicore Pharma AB

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Drug Profiles

(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMA-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-6A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Dormant Projects

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Featured News & Press Releases

Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments

May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis

Feb 05, 2014: Spinifex Pharmaceuticals’ Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia

Oct 18, 2013: Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch

Mar 27, 2013: Spinifex Pharma Receives AUD1.5m In R&D Tax Incentive For Research Activities Related To Discovery Of Treatments For Pain

Feb 18, 2013: Vicore Pharma Announces Publication Of Article In Nature

Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy

Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting

Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease

Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia

Sep 19, 2011: Spinifex Announces Start Of Phase II Proof-of-Concept Trial Of EMA401 In Postherpetic Neuralgia

Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting

Aug 23, 2011: Additional Funds To Broaden EMA401 Phase II Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by CJ HealthCare Corp., H1 2016

Pipeline by MorphoSys AG, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Vicore Pharma AB, H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • CJ HealthCare Corp.
  • MorphoSys AG
  • Novartis AG
  • Vicore Pharma AB
  • MORE
The recently published report 'Type-2 Angiotensin II Receptor - Pipeline Review, H1 2016'; Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Furthermore, Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

The report 'Type-2 Angiotensin II Receptor - Pipeline Review, H1 2016' outlays comprehensive information on the Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively.

Note: Product cover images may vary from those shown
5 of 6
CJ HealthCare Corp.
MorphoSys AG
Novartis AG
Vicore Pharma AB
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll